Please login to the form below

Not currently logged in
Email:
Password:

Astellas posts positive bladder therapy data

Astellas has reported positive data from a phase III trial for its overactive bladder therapy candidate mirabegron

Astellas has reported positive data from a phase III trial for its overactive bladder therapy candidate mirabegron.

The data showed that 12 weeks of treatment with mirabegron once-daily led to significant improvements in the number of incontinence episodes, the frequency of urination per 24 hours, and patient-reported outcomes including disease perception, symptom interference and quality of life.

Mirabegron is a selective beta-3 adrenoceptor antagonist designed to facilitate filling of the bladder and storage of urine. A marketing authorisation application for the drug was submitted in Japan in June 2010.

Astellas expects to make regulatory filings in the US and Europe during the second half of 2011.

19th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics